The role of urological pathology in the development of terminal renal failure
- Authors: Simonov P.A.1, Firsov M.A.1,2, Dunc D.A.2, Bezrukov E.A.2,3, Ivliev S.V.1
-
Affiliations:
- Regional Clinical Hospital
- Voyno-Yasenetsky Krasnoyarsk State Medical University
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 24, No 10 (2022)
- Pages: 759-762
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/120392
- DOI: https://doi.org/10.26442/20751753.2022.10.201927
- ID: 120392
Cite item
Full Text
Abstract
Background. Chronic kidney disease (CKD) is one of the most serious and pressing health problems worldwide today. The end stage of CKD leads to disability and dramatically reduces the quality of life, which is caused by the need for continuous renal replacement therapy. The causes of CKD are various and are often caused by urological pathology.
Materials and methods. Five hundred eighty seven case histories of patients with CKD on renal replacement therapy in the Krasnoyarsk Territory for 2022 were analyzed. Most of them were patients with chronic glomerulonephritis (38%) and urological diseases (29%). Other reasons that led to hemodialysis are diabetic nephropathy (12%), hypertensive nephropathy (8%), mixed nephropathy (5%). Systemic diseases with kidney damage, oncological diseases, rejection of a kidney transplant, genetic diseases – 2% each.
Results. Оne hundred and seventy patients with urological diseases are on program hemodialysis. The mean age of this group of patients was 56.2 years. The incidence of CKD varies slightly between men (48%) and women (52%). The structure of the incidence of urological pathology is as follows: all patients somehow had signs of chronic pyelonephritis. Of 170 people, only 15% had primary chronic pyelonephritis as the main cause of end-stage CKD. The remaining 81% of patients showed signs of secondary pyelonephritis. Patients with polycystic kidney disease accounted for 44%, patients with urolithiasis – 13%, patients with anomalies in the development of the kidneys and urinary tract – 7%, vesicoureteral reflux, with prostate adenoma – 5% patients with signs of a neurogenic bladder 3% and 3% – patients with ureteral structure. Patients with oncological pathology accounted for 4%.
Conclusion. Over the past decade, the structure of diseases of patients on hemodialysis has changed. Due to the more accessible diagnostic service in the region, the proportion of urological pathologies in patients is increasing. At the same time, the timely use of reconstructive, minimally invasive, nephron-sparing operations can reduce the risks of progression of CKD. However, the number of end-stage patients is steadily increasing, requiring continued development of the hemodialysis service and other forms of renal replacement therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Pavel A. Simonov
Regional Clinical Hospital
Author for correspondence.
Email: wildsnejok@mail.ru
ORCID iD: 0000-0002-9114-3052
urologist, Regional Clinical Hospital
Russian Federation, KrasnoyarskMikhail A. Firsov
Regional Clinical Hospital; Voyno-Yasenetsky Krasnoyarsk State Medical University
Email: firsma@mail.ru
ORCID iD: 0000-0002-0887-0081
Cand. Sci. (Med.), Regional Clinical Hospital, Voyno-Yasenetsky Krasnoyarsk State Medical University
Russian Federation, Krasnoyarsk; KrasnoyarskDaria A. Dunc
Voyno-Yasenetsky Krasnoyarsk State Medical University
Email: dashaduntz@mail.ru
Student, Voyno-Yasenetsky Krasnoyarsk State Medical University
Russian Federation, KrasnoyarskEugene A. Bezrukov
Voyno-Yasenetsky Krasnoyarsk State Medical University; Sechenov First Moscow State Medical University (Sechenov University)
Email: eabezrukov@rambler.ru
ORCID iD: 0000-0002-2746-5962
D. Sci. (Med.), Voyno-Yasenetsky Krasnoyarsk State Medical University, Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation, Krasnoyarsk; MoscowSergei V. Ivliev
Regional Clinical Hospital
Email: sergivl@yandex.ru
ORCID iD: 0000-0003-0606-872X
Cand. Sci. (Med.), Regional Clinical Hospital
Russian Federation, KrasnoyarskReferences
- GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33.
- Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052-90.
- Brück K, Stel VS, Gambaro G, et al.; European CKD Burden Consortium. CKD Prevalence Varies across the European General Population. J Am Soc Nephrol. 2016;27(7):2135-47. doi: 10.1681/ASN.2015050542
- Muiru AN, Charlebois ED, Balzer LB, et al. The epidemiology of chronic kidney disease (CKD) in rural East Africa: A population-based study. PLoS One. 2020;15(3):e0229649. doi: 10.1371/journal.pone.0229649
- Duan JY, Duan GC, Wang CJ, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey. BMC Nephrol. 202;21(1):115. doi: 10.1186/s12882-020-01761-5
- Дудко М.Ю., Котенко О.Н., Шутов Е.В., Васина Н.В. Эпидемиология хронической болезни почек среди жителей города Москвы. Клиническая нефрология. 2019;11(3):37-41 [Dudko MIu, Kotenko ON, Shutov EV, Vasina NV. Epidemiologiia khronicheskoi bolezni pochek sredi zhitelei goroda Moskvy. Klinicheskaia nefrologiia. 2019;11(3):37-41 (in Russian)].
- Николаев А.Ю. Диагностические ошибки и диализные осложнения – факторы неблагоприятного прогноза в 4–5-й стадиях хронической болезни почек. Клиническая нефрология. 2018;2:76-9 [Nikolaev AIu. Diagnosticheskie oshibki i dializnye oslozhneniia-faktory neblagopriiatnogo prognoza v 4–5-i stadiiakh khronicheskoi bolezni pochek. Klinicheskaia nefrologiia. 2018;2:76-9 (in Russian)].
- Котенко О.Н. Хроническая болезнь почек. Проблемы и решения. Московская медицина. 2018;1:21-3 [Kotenko ON. Chronic kidney disease: problems and solutions. Moscow Medicine. 2018;1:21-3 (in Russian)].
- Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975-82.
- Андрусев А.М., Аникин И.В., Зиновьева Н.А., и др. Заместительная почечная терапия хронической болезни почек 5 стадии в Российской Федерации 2015–2109 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Нефрология и диализ. 2021;23(3):255-329 [Andrusev AM, Anikin IV, Zinov'eva NA, et al. Zamestitel'naia pochechnaia terapiia khronicheskoi bolezni pochek 5 stadii v Rossiiskoi Federatsii 2015–2109 gg. Otchet po dannym Obshcherossiiskogo Registra zamestitel'noi pochechnoi terapii Rossiiskogo dializnogo obshchestva. Nefrologiia i dializ. 2021;23(3):255-329 (in Russian)].
- USRDS, 2019. Annual Data Report. Electronic publication. Available at: https://www.usrds.org/annual-data-report/current-adr/ Accessed: 25.09.2020.
- Фирсов М.А., Капсаргин Ф.П., Лалетин Д.И., и др. Особенности течения послеоперационного периода урологических больных с терминальной почечной недостаточностью. Уральский медицинский журнал. 2016;1:35-8 [Firsov MA, Kapsargin FP, Laletin DI, et al. Osobennosti techeniia posleoperatsionnogo perioda urologicheskikh bol'nykh s terminal'noi pochechnoi nedostatochnost'iu. Ural'skii meditsinskii zhurnal. 2016;1:35-8 (in Russian)].
